Evofem Biosciences Inc
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recur… Read more
Evofem Biosciences Inc (EVFM) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: 0.034x
Based on the latest financial reports, Evofem Biosciences Inc (EVFM) has a cash flow conversion efficiency ratio of 0.034x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.41 Million) by net assets ($-71.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Evofem Biosciences Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Evofem Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Evofem Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evofem Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ExpreS2ion Biotech Holding AB (publ)
F:5JD0
|
-0.314x |
|
Trenchant Technologies Capital Corp.
PINK:AITTF
|
-0.049x |
|
ABERCROMBIE FTCH-A
BE:AFT
|
0.135x |
|
Meiwu Technology Co Ltd
NASDAQ:WNW
|
0.115x |
|
Cleantech Power Corp.
PINK:PWWRF
|
-0.220x |
|
Nuzee Inc
NASDAQ:NUZE
|
4.967x |
|
Cascadero Copper Corporation
PINK:CCEDF
|
0.168x |
|
Acdc Metals Ltd
AU:ADC
|
-0.074x |
Annual Cash Flow Conversion Efficiency for Evofem Biosciences Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Evofem Biosciences Inc from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-71.26 Million | $-3.88 Million | 0.055x | -59.57% |
| 2023-12-31 | $-66.51 Million | $-8.97 Million | 0.135x | -86.25% |
| 2022-12-31 | $-71.80 Million | $-70.41 Million | 0.981x | +103.17% |
| 2021-12-31 | $4.74 Million | $-146.67 Million | -30.942x | +60.24% |
| 2020-12-31 | $1.35 Million | $-104.83 Million | -77.824x | -2108.57% |
| 2019-12-31 | $15.64 Million | $-55.10 Million | -3.524x | -245.66% |
| 2018-12-31 | $-23.36 Million | $-56.50 Million | 2.419x | +179.84% |
| 2017-12-31 | $2.71 Million | $-8.20 Million | -3.030x | -122.08% |
| 2016-12-31 | $11.91 Million | $-16.25 Million | -1.364x | +14.33% |
| 2015-12-31 | $23.81 Million | $-37.91 Million | -1.592x | -985.46% |
| 2014-12-31 | $65.25 Million | $-9.57 Million | -0.147x | +99.09% |
| 2013-12-31 | $797.29K | $-12.90 Million | -16.185x | -1934.38% |
| 2012-12-31 | $9.30 Million | $-7.40 Million | -0.796x | -- |